+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 12Years +
All Genders
ID07794514

Comparison of Belumosudil and Ruxolitinib for Steroid-Refractory or Breakthrough Hepatic cGVHD A Multicenter Randomized Study with Treatment Switch for Pretreated Patients

Led by First Affiliated Hospital of Zhejiang University · Updated on 2026-08-31

170

Participants Needed

1

Research Sites

39 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are comparing two second-line treatments, ruxolitinib and belumosudil, for patients with steroid-refractory or breakthrough hepatic chronic graft-versus-host disease cGVHD following allogeneic hematopoietic stem cell transplantation allo-HSCT. The study aims to determine differences in liver response rates, safety, tolerability, steroid reduction, and long-term outcomes between these treatments. Two patient groups are included those new to these drugs and those switching treatments due to lack of response or progression. Participants will receive assigned oral treatments based on their group and randomization. Cohort 1 includes patients who have not previously taken either drug and are randomized to one. Cohort 2 involves patients who switch from one drug to the other if their hepatic cGVHD worsens or does not respond. Treatments follow standard approved dosing schedules. The study includes a 24-week primary treatment period with ongoing follow-up until disease progression or treatment discontinuation. During the study, participants undergo regular monitoring for treatment effectiveness and safety, including liver function tests, cGVHD scoring, and adverse event tracking. Blood samples are collected at baseline and various times on treatment for biomarker research. Researchers assess liver response at 24 weeks as the primary outcome, with secondary outcomes including response duration, survival, steroid tapering, quality of life, and safety. The total participation time extends up to two years for some assessments.

CONDITIONS

Brief Title

Belumosudil Versus Ruxolitinib for Steroid-Refractory or Breakthrough Hepatic cGVHD

Research Team

F

Fei Gao

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here